Furthermore, in the phase II clinical trial, a combination of IFNα and chemotherapy (Oxaliplatin/Adriamycin/5-Fluorouracil) showed manageable toxicity and improved survival of patients with advanced hepatocellular carcinoma [25]. Here, IFNA17 is linked to hepatocellular carcinoma.